Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 4N222 | IM |
received Priorix vaccine intramuscularly; Out of recommended age range; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 63-year-old male patient who received MMR (Priorix) (batch number 4N222, expiry date 13-MAR-2026) for prophylaxis. On 21-MAR-2025, the patient received Priorix (intramuscular). On 21-MAR-2025, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: received Priorix vaccine intramuscularly) and inappropriate age at vaccine administration (Verbatim: Out of recommended age range). The outcome of the subcutaneous injection formulation administered by other route and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 21-MAR-2025 The pharmacist reported that the patient received an intramuscular dose of Priorix which led to, subcutaneous injection formulation administered by other route. The reporter mentioned that aside from the administration error, it was also noted that the patient was outside of the age range described in the prescribing information which led to, inappropriate age at vaccine administration. The Vaccine Administration Facility is the same as Primary Reporter.